649 Shares in Stryker Co. (NYSE:SYK) Purchased by True Link Financial Advisors LLC

True Link Financial Advisors LLC bought a new position in shares of Stryker Co. (NYSE:SYK) in the 4th quarter, Holdings Channel.com reports. The institutional investor bought 649 shares of the medical technology company’s stock, valued at approximately $234,000.

Several other institutional investors also recently modified their holdings of the stock. Trueblood Wealth Management LLC grew its position in shares of Stryker by 10.5% during the 4th quarter. Trueblood Wealth Management LLC now owns 3,140 shares of the medical technology company’s stock worth $1,131,000 after buying an additional 299 shares during the period. Diversify Wealth Management LLC lifted its stake in Stryker by 4.2% in the 4th quarter. Diversify Wealth Management LLC now owns 9,205 shares of the medical technology company’s stock valued at $3,366,000 after acquiring an additional 373 shares in the last quarter. Terra Nova Asset Management LLC lifted its stake in Stryker by 0.4% in the 4th quarter. Terra Nova Asset Management LLC now owns 8,344 shares of the medical technology company’s stock valued at $3,004,000 after acquiring an additional 32 shares in the last quarter. Annex Advisory Services LLC lifted its stake in Stryker by 63.0% in the 4th quarter. Annex Advisory Services LLC now owns 13,549 shares of the medical technology company’s stock valued at $4,878,000 after acquiring an additional 5,235 shares in the last quarter. Finally, Grove Bank & Trust lifted its stake in Stryker by 43.4% in the 4th quarter. Grove Bank & Trust now owns 175 shares of the medical technology company’s stock valued at $63,000 after acquiring an additional 53 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Stock Performance

Shares of NYSE SYK opened at $383.91 on Monday. The firm has a market cap of $146.35 billion, a price-to-earnings ratio of 41.15, a P/E/G ratio of 2.51 and a beta of 0.95. Stryker Co. has a one year low of $307.23 and a one year high of $398.20. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock’s fifty day moving average price is $375.51 and its two-hundred day moving average price is $358.98.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.46 EPS. On average, equities analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.84 per share. This is a positive change from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Tuesday, December 31st. Stryker’s dividend payout ratio is 36.01%.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 5.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have commented on SYK shares. Wells Fargo & Company boosted their target price on Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. BTIG Research boosted their target price on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Evercore ISI boosted their target price on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Finally, Robert W. Baird upped their price objective on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average price target of $405.80.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.